These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

927 related items for PubMed ID: 30772960

  • 41. 68Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients.
    Liu C, Liu T, Zhang N, Liu Y, Li N, Du P, Yang Y, Liu M, Gong K, Yang X, Zhu H, Yan K, Yang Z.
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1852-1861. PubMed ID: 29717333
    [Abstract] [Full Text] [Related]

  • 42. Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach.
    Albisinni S, Artigas C, Aoun F, Biaou I, Grosman J, Gil T, Hawaux E, Limani K, Otte FX, Peltier A, Sideris S, Sirtaine N, Flamen P, van Velthoven R.
    BJU Int; 2017 Aug; 120(2):197-203. PubMed ID: 27981732
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
    van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B, Nguyen Q, Ho B, Emmett L.
    BJU Int; 2016 May; 117(5):732-9. PubMed ID: 26683282
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. A prospective intra-individual comparison of [68Ga]Ga-PSMA-11 PET/CT, [68Ga]Ga-NODAGAZOL PET/CT, and [99mTc]Tc-MDP bone scintigraphy for radionuclide imaging of prostate cancer skeletal metastases.
    Lawal IO, Mokoala KMG, Mahapane J, Kleyhans J, Meckel M, Vorster M, Ebenhan T, Rösch F, Sathekge MM.
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):134-142. PubMed ID: 32424485
    [Abstract] [Full Text] [Related]

  • 48. Unspecific 18F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate Cancer.
    Seifert R, Telli T, Opitz M, Barbato F, Berliner C, Nader M, Umutlu L, Stuschke M, Hadaschik B, Herrmann K, Fendler WP.
    J Nucl Med; 2023 May; 64(5):738-743. PubMed ID: 36460340
    [Abstract] [Full Text] [Related]

  • 49. The value of 68 Ga-PSMA-11 PET/CT in patients with prostate cancer and inconclusive standard imaging at primary staging.
    Nalliah S, Zacho HD.
    Nucl Med Commun; 2022 Oct 01; 43(10):1092-1098. PubMed ID: 35950348
    [Abstract] [Full Text] [Related]

  • 50. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
    Lawal IO, Ankrah AO, Mokgoro NP, Vorster M, Maes A, Sathekge MM.
    Prostate; 2017 Aug 01; 77(11):1205-1212. PubMed ID: 28649735
    [Abstract] [Full Text] [Related]

  • 51. Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer?
    Raju S, Sharma A, Patel C, Sahoo R, Das CJ, Kumar S, Sharma A, Kumar R.
    Nucl Med Commun; 2020 Nov 01; 41(11):1183-1188. PubMed ID: 32796451
    [Abstract] [Full Text] [Related]

  • 52. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
    van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, Stricker PD.
    BJU Int; 2017 Feb 01; 119(2):209-215. PubMed ID: 27207581
    [Abstract] [Full Text] [Related]

  • 53. [89Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [68Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis.
    Rosar F, Burgard C, Larsen E, Khreish F, Marlowe RJ, Schaefer-Schuler A, Maus S, Petto S, Bartholomä M, Ezziddin S.
    Cancer Imaging; 2024 Feb 22; 24(1):27. PubMed ID: 38389092
    [Abstract] [Full Text] [Related]

  • 54. 68Ga-PSMA I&T PET/CT for primary staging of prostate cancer.
    Cytawa W, Seitz AK, Kircher S, Fukushima K, Tran-Gia J, Schirbel A, Bandurski T, Lass P, Krebs M, Połom W, Matuszewski M, Wester HJ, Buck AK, Kübler H, Lapa C.
    Eur J Nucl Med Mol Imaging; 2020 Jan 22; 47(1):168-177. PubMed ID: 31529265
    [Abstract] [Full Text] [Related]

  • 55. Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial.
    de Feria Cardet RE, Hofman MS, Segard T, Yim J, Williams S, Francis RJ, Frydenberg M, Lawrentschuk N, Murphy DG, De Abreu Lourenco R.
    Eur Urol; 2021 Mar 22; 79(3):413-418. PubMed ID: 33341285
    [Abstract] [Full Text] [Related]

  • 56. Clinical parameters and nomograms for predicting lymph node metastasis detected with 68 Ga-PSMA-PET/CT in prostate cancer patients candidate to definitive radiotherapy.
    Onal C, Ozyigit G, Oymak E, Guler OC, Hurmuz P, Tilki B, Reyhan M, Tuncel M, Akyol F.
    Prostate; 2021 Jul 22; 81(10):648-656. PubMed ID: 33949694
    [Abstract] [Full Text] [Related]

  • 57. Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer.
    Schmuck S, Nordlohne S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, Ross TL, Bengel FM, Derlin T.
    Eur J Nucl Med Mol Imaging; 2017 Jun 22; 44(6):960-968. PubMed ID: 28280856
    [Abstract] [Full Text] [Related]

  • 58. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
    Baumann R, Koncz M, Luetzen U, Krause F, Dunst J.
    Strahlenther Onkol; 2018 Apr 22; 194(4):318-324. PubMed ID: 29181556
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. The role of (68Ga)PSMA I&T in biochemical recurrence after radical prostatectomy: detection rate and the correlation between the level of PSA, Gleason score, and the SUVmax.
    Yilmaz U, Komek H, Can C, Altindag S.
    Ann Nucl Med; 2019 Aug 22; 33(8):545-553. PubMed ID: 31069696
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 47.